Literature DB >> 22229478

The effects of sildenafil on rectal sensitivity and tone in patients with the irritable bowel syndrome.

M T Gonçalves de Medeiros1, R B de Oliveira, A A dos Santos, D M de Leopoldino, M C Oliveira Lima, R Arrais Nobre, M Â Nobre e Souza.   

Abstract

BACKGROUND: Visceral tone supposedly affects gut sensitivity in irritable bowel syndrome (IBS). Sildenafil increases nitric oxide and influences visceral compliance. AIM: To evaluate the effects of sildenafil tone inhibition on rectal sensitivity.
METHODS: Eight controls and 21 IBS patients (Rome II) were enrolled in a double-blind study, after dosing with placebo or sildenafil (50 mg p.o.). Thresholds for first sensation, first desire to defecate, pain and supraliminar pain were the sensory endpoints, measured with a barostat and 600-mL rectal bag. Pain (100-mm VAS) and depression-anxiety (Hamilton questionnaire) were scored.
RESULTS: Irritable bowel syndrome rectal compliance and sensory-endpoint thresholds were similar to controls. Five IBS patients had pain threshold lower than controls 95% confidence interval (hypersensitive). Depression score was greater in IBS than controls (11.9 ± 1.3 vs. 6.3 ± 2.5, P = 0.036). In IBS, pain intensity was nonsignificantly higher (37.6 ± 5.3 mm vs. 23.4 ± 8.5 mm, P = 0.064) and supraliminar pain intensity was greater (45.6 ± 5.4 mm vs. 25.9 ± 5.1 mm, P = 0.044) than controls. IBS rectal relaxation increased volume (155.4 ± 41.3 mL vs. 118.8 ± 47.7 mL, P = 0.004) and tension (193.1 ± 118.6 mmHg mL(-1) vs. 133.2 ± 98.1 mmHg mL(-1) , P = 0.019) for triggering first desire to defecate but not for other perceptions. Sildenafil increased volume for both first desire to defecate and pain in the hypersensitive IBS patients. Sildenafil increased rectal compliance only in diarrhoea-IBS. Mixed-IBS obtained higher anxiety (12.9 ± 1.3 vs. 5.9 ± 3.1, P < 0.05) and depression scores (13.9 ± 1.9 vs. 6.3 ± 2.5, P < 0.05) and reported more intense supraliminar pain (53.6 ± 9.8 mm vs. 25.9 ± 5.1 mm, P < 0.05) than controls.
CONCLUSIONS: Rectal relaxation following dosing with sildenafil 50 mg increased the first desire to defecate threshold in IBS as a whole, but decreased pain only in the hypersensitive subset. Mixed-IBS presented higher supraliminar pain and anxiety-depression scores.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22229478     DOI: 10.1111/j.1365-2036.2011.04977.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Conditioned pain modulation in women with irritable bowel syndrome.

Authors:  Monica E Jarrett; Robert J Shulman; Kevin C Cain; Wimon Deechakawan; Lynne T Smith; Philippe Richebé; Margaret Eugenio; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2014-01-24       Impact factor: 2.522

Review 2.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 3.  The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis.

Authors:  Changhyun Lee; Eunyoung Doo; Ji Min Choi; Seung-Ho Jang; Han-Seung Ryu; Ju Yup Lee; Jung Hwan Oh; Jung Ho Park; Yong Sung Kim
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

4.  Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies.

Authors:  Qing-E Zhang; Fei Wang; Geng Qin; Wei Zheng; Chee H Ng; Gabor S Ungvari; Zhen Yuan; Songli Mei; Gang Wang; Yu-Tao Xiang
Journal:  Int J Biol Sci       Date:  2018-08-15       Impact factor: 6.580

5.  The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: a network meta-analysis.

Authors:  Zhichao Hu; Meixuan Li; Liang Yao; Yinshu Wang; Enkang Wang; Jianye Yuan; Fengyun Wang; Kehu Yang; Zhaoxiang Bian; Linda L D Zhong
Journal:  BMC Gastroenterol       Date:  2021-01-07       Impact factor: 3.067

6.  Novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment.

Authors:  Ying Xu; Chuang Wang; Jonathan J Klabnik; James M O'Donnell
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.